Journal article icon

Journal article

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Abstract:

Background: No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


Expand authors...
Wellcome Trust More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Lancet Journal website
Volume:
395
Issue:
10236
Pages:
1569-1578
Publication date:
2020-04-29
Acceptance date:
2020-04-21
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Pmid:
32423584
Language:
English
Keywords:
Pubs id:
1105164
Local pid:
pubs:1105164
Deposit date:
2020-06-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP